Guest guest Posted March 23, 2011 Report Share Posted March 23, 2011 File under interesting but earlier .. good safety profile, a likely candidate for investigation with radiotherapy/RIT. - Karl Imexon is a small molecule agent currently in Phase I clinical trials. This agent has been shown to increase intracellular oxidants (levels of oxidants within cells), inducing apoptosis in hematologic cancer cells. It appears also to sensitize cells to the effects of radiotherapy. Clinical trial: Imexon for Relapsed Follicular and Aggressive Lymphomas (ULYM11011) This study is not yet open for participant recruitment. Verified by University of Rochester, March 2011 http://clinicaltrials.gov/ct2/show/NCT01314014 (two US centers) report on safety in a similar condition - MM: http://journals.lww.com/anti-cancerdrugs/Abstract/2010/08000/Combined_phase_ I_II_study_of_imexon__AOP99_0001_.7.aspx Technical (very) background: The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response http://clincancerres.aacrjournals.org/content/13/11/3388.full All the best, ~ Karl Patients Against Lymphoma Patients Helping Patients Non-profit | Independent | Evidence-based www.lymphomation.org | Current News: http://bit.ly/f2A0T How to Help: www.lymphomation.org/how-to-help.htm Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.